Norris, Daniel A.

Tau-targeting antisense oligonucleotide MAPTRx in mild Alzheimer’s disease: a phase 1b, randomized, placebo-controlled trial

Mummery, C. J., Börjesson-Hanson, A., Blackburn, D. J., Vijverberg, E. G. B., De Deyn, P. P., Ducharme, S., Jonsson, M., Schneider, A., Rinne, J. O., Ludolph, A. C., et al. (2023) · Nature Medicine

Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research

Cited by 347

Pharmacology of a Central Nervous System Delivered 2′-O-Methoxyethyl–Modified Survival of Motor Neuron Splicing Oligonucleotide in Mice and Nonhuman Primates

Rigo, F., Chun, S. J., Norris, D. A., Hung, G., Lee, S., Matson, J., Fey, R. A., Gaus, H., Hua, Y., Grundy, J. S., et al. (2014) · The Journal of Pharmacology and Experimental Therapeutics

Neurogenetic and Muscular Disorders ResearchRNA Interference and Gene Delivery

Cited by 283

Design of the First-in-Human study of IONIS-MAPTRx, a Tau-lowering antisense oligonucleotide, in patients with alzheimer disease (S2.006)

Mignon, L., Kordasiewicz, H., Lane, R., Smith, A., Miller, T., Narayanan, P., Swayze, E., Norris, D., Fitzsimmons, B., & Bennett, F. (2018) · Neurology

Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research

Cited by 29

Effects of IONIS-HTTRx in Patients with Early Huntington’s Disease, Results of the First HTT-Lowering Drug Trial (CT.002)

Tabrizi, S., Leavitt, B., Kordasiewicz, H., Czech, C., Swayze, E., Norris, D. A., Baumann, T., Gerlach, I., Schobel, S., Smith, A., et al. (2018) · Neurology

Genetic Neurodegenerative DiseasesAmyotrophic Lateral Sclerosis Research

Cited by 26